CULTURE MEDIUM CONTAINING KINASE INHIBITORS. AND USES THEREOF

(19)

(11)

EP 1 999 249 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	15.02.2012 Bulletin 2012/07

(45)	Mention of the grant of the patent:
	26.10.2011 Bulletin 2011/43

(21)	Application number: 07732217.0

(22)	Date of filing: 30.03.2007

(51)

International Patent Classification (IPC):

C12N 5/02^(2006.01)

(86)	International application number:
	PCT/GB2007/001163

(87)	International publication number:
	WO 2007/113505 (11.10.2007 Gazette 2007/41)

(54)	CULTURE MEDIUM CONTAINING KINASE INHIBITORS. AND USES THEREOF KULTURMEDIUM MIT KINASEHEMMERN UND VERWENDUNG MILIEU DE CULTURE CONTENANT DES INHIBITEURS DE KINASE ET UTILISATION DE CELUI-CI

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

(30)

Priority:

30.03.2006 GB 0606392
01.08.2006 GB 0615327

(43)	Date of publication of application:
	10.12.2008 Bulletin 2008/50

(60)	Divisional application:
	11182239.1

(73)	Proprietor: The University Court Of The University of Edinburgh
	South Bridge Edinburgh EH8 9YL (GB)

(72)	Inventors:
	YING, Qi-Long Los Angeles, CA 90033 (US) SMITH, Austin, Gerard Cambridge CB2 1QT (GB)

(74)	Representative: Schlich, George William et al
	Schlich & Co 34 New Road Littlehampton West Sussex BN17 5AT Littlehampton West Sussex BN17 5AT (GB)

(56)

References cited: :

WO-A-2005/039486
US-A1- 2006 083 711

WO-A-2005/094830

QUEVEDO CELIA ET AL: "Two different signal transduction pathways are implicated in the regulation of initiation factor 2B activity in insulin-like growth factor-1-stimulated neuronal cells" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 25, 23 June 2000 (2000-06-23), pages 19192-19197, XP002438559 ISSN: 0021-9258
HETMAN MICHAL ET AL: "ERK1/2 antagonizes glycogen synthase kinase-3beta-induced apoptosis in cortical neurons." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 51, 20 December 2002 (2002-12-20), pages 49577-49584, XP002438560 ISSN: 0021-9258
ALONSO M ET AL: "GSK-3 inhibitors: Discoveries and developments." CURRENT MEDICINAL CHEMISTRY, vol. 11, no. 6, March 2004 (2004-03), pages 755-763, XP009085415 ISSN: 0929-8673
ENGLISH J M ET AL: "Pharmacological inhibitors of MAPK pathways" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, HAYWARTH, GB, vol. 23, no. 1, 1 January 2002 (2002-01-01), pages 40-45, XP004333247 ISSN: 0165-6147
MEIJER L ET AL: "Pharmacological inhibitors of glycogen synthase kinase 3" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 25, no. 9, September 2004 (2004-09), pages 471-480, XP004552644 ISSN: 0165-6147
PALING N R D ET AL: "REGULATION OF EMBRYONIC STEM CELL SELF-RENEWAL BY PHOSPHOINOSITIDE 3-KINASE-DEPENDENT SIGNALING" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 279, no. 46, 24 August 2004 (2004-08-24), pages 48063-48070, XP002380573 ISSN: 0021-9258

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).